Schor Chen 4

What Happened

• Schor Chen, President & CEO and a director of Adicet Bio, was granted 55,000 shares on 2026-06-19. The grant is reported as an award/derivative with a reported acquisition price of $0.00 (i.e., no cash paid). This is a compensation award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-19; filing date (Form 4): 2026-06-23 (appears to be one business day late relative to the 2-business-day Form 4 deadline).
• Amount granted: 55,000 shares; reported acquisition price: $0.00.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Footnote: 1/48th of the shares vest on each of the next 48 monthly anniversaries of the grant date; partial acceleration of vesting may occur tied to specified performance milestones, provided the reporting person remains in service as of each vesting date.
• Transaction type code: A (award/grant); treated as a derivative award subject to vesting.

Context

• This award is a typical form of executive compensation intended to align management with long-term shareholder interests; because it vests over four years and may accelerate only on certain milestones, it does not represent immediately tradable shares.
• Awards (vs. purchases or sales) are informational about compensation and retention, not direct bullish or bearish trading signals.